Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection
Primary objectives: Evaluate the progression-free survival at 9 months (according to RECIST 1.1) according to the investigator. Primary endpoints: Progression-free survival at 9 months: percentage of
CTLA-4 is a clinically validated antibody target for cancer immunotherapy. Toxicity, which is linked to efficacy in available anti-CTLA-4 regimens has, however, restricted their use and precluded full